Acacia Pharma Group plc
20 March 2018
Change in Directors' interests in the shares of Acacia Pharma Group plc ("Acacia Pharma" or the "Company")
This notification is made in accordance with the Company's obligations under the Market Abuse Regulation.
The following transactions have taken place in relation to the executive directors under the Company's share plans.
Performance Share Plan
On 19 March 2018, the following directors were granted conditional awards ("Awards") under the Acacia Pharma Group plc Performance Share Plan (the "Plan"). Julian Gilbert was granted an Award over 96,875 Ordinary Shares and Christine Soden was granted an Award over 75,000 ordinary shares of £0.02 pence each in the Company ("Ordinary Shares") in each case in the form of options with an exercise price of £0.02 per share
In each case the Awards were granted over Ordinary Shares equal to 100% of salary at the point of grant as allowed for in the Prospectus for the Initial Global Offering of the Company's shares dated 2 March 2018, calculated at 320p per share (being the market price of the shares at the time of the Offering). No consideration was paid for the grant of these Awards.
The Awards will normally vest on 18 March 2021, subject to the satisfaction of the applicable performance conditions being met over the period to 31 December 2020.
Notification and public disclosure of transactions by persons discharging managerial responsibilities.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||
| a) | Name | Julian Gilbert | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/status | CEO, Director | ||||||
| b) | Initial notification /Amendment | Initial Notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | Acacia Pharma Group plc | ||||||
| b) | LEI | 213800SLDKXWKT6E3381 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| 1 | Description of the financial instrument, type of instrument | Ordinary Shares of £0.02 | ||||||
| Identification code | GB00BYWF9Y76 | |||||||
| Nature of the transaction | Grant of conditional awards under the Company's Performance Share Plan | |||||||
| Price(s) and volume(s) | ||||||||
| Price(s) | Volume(s) | Total | ||||||
| £0 | 96,875 | £0 | ||||||
| Aggregated information | ||||||||
| 96,875 | |||||||
| £0 | |||||||
| Date of the transaction | 19 March 2018 | |||||||
| Place of the transaction | Outside a trading venue | |||||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Christine Soden | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | CFO, Director | ||||
| b) | Initial notification /Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Acacia Pharma Group plc | ||||
| b) | LEI | 213800SLDKXWKT6E3381 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| 1. | Description of the financial instrument, type of instrument | Ordinary Shares of £0.02 | ||||
| Identification code | GB00BYWF9Y76 | |||||
| Nature of the transaction | Grant of conditional awards under the Company's Performance Share Plan | |||||
| Price(s) and volume(s) | ||||||
| Price(s) | Volume(s) | Total | ||||
| £0 | 75,000 | £0 | ||||
| Aggregated information | ||||||
| 75,000 | |||||
| £0 | |||||
| Date of the transaction | 19 March 2018 | |||||
| Place of the transaction | Outside a trading venue | |||||
Contacts
Acacia Pharma Group plc
Christine Soden, CFO
+44 1223 875130
IR@acaciapharma.com